Related Experiment Videos
Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites
Cancer Treatment Reports
|September 1, 1977
Summary
This study investigated chemotherapy regimens for diffuse histiocytic lymphoma (DHL). Adding methotrexate and cytosine arabinoside showed promising survival benefits for DHL patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Diffuse histiocytic lymphoma (DHL) is an aggressive non-Hodgkin lymphoma.
- Optimizing chemotherapy regimens is crucial for improving patient outcomes in DHL.
Purpose of the Study:
- To evaluate the efficacy of three chemotherapy regimens for DHL.
- To assess the impact of specific drug combinations on patient survival.
Main Methods:
- Thirty patients with DHL received one of three treatment regimens.
- Regimens included cyclophosphamide, vincristine, methotrexate with citrovorum factor rescue, and cytosine arabinoside.
- Patient responses and survival times were analyzed.
Main Results:
- Twelve patients achieved a complete response with a predicted 50% survival of at least 76 months.
- Partial responders (11 patients) had a median survival of 18 months.
- Nonresponders (seven patients) had a median survival of 6 months.
Conclusions:
- The addition of methotrexate and cytosine arabinoside may benefit DHL therapy.
- Chemotherapy efficacy in DHL might be influenced by the scheduling and dosage of these agents.